Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTO protocol in medication-related osteonecrosis of the jaw (MRONJ)
2022-002669-13Phase 2Active
- Sponsor
- CHU de Limoges
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentoxifylline in medication-related osteonecrosis of the jaw (MRONJ), sponsored by CHU de Limoges. Primary endpoint: Healing at 12 months (primary endpoint). Started Aug 2022; status: active.
02
Drugs
pentoxifylline
03
Conditions
medication-related osteonecrosis of the jaw (MRONJ)
Beyond the preview
Go deeper on 2022-002669-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002669-13.